Business Description
Clinuvel Pharmaceuticals Ltd
ISIN : AU000000CUV3
Share Class Description:
ASX:CUV: Ordinary SharesTotal Employee Number:
16Description
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 719.13 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | 8.53 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 12.17 | |||||
Beneish M-Score | -2.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.1 | |||||
3-Year EBITDA Growth Rate | 16.3 | |||||
3-Year EPS without NRI Growth Rate | 21.2 | |||||
3-Year FCF Growth Rate | 2.1 | |||||
3-Year Book Growth Rate | 23.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.78 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.77 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.21 | |||||
9-Day RSI | 62.07 | |||||
14-Day RSI | 61.6 | |||||
3-1 Month Momentum % | -0.22 | |||||
6-1 Month Momentum % | -29.19 | |||||
12-1 Month Momentum % | -9.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.64 | |||||
Quick Ratio | 14.17 | |||||
Cash Ratio | 13.05 | |||||
Days Inventory | 194.39 | |||||
Days Sales Outstanding | 72.25 | |||||
Days Payable | 137.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.48 | |||||
Dividend Payout Ratio | 0.08 | |||||
3-Year Dividend Growth Rate | 26 | |||||
Forward Dividend Yield % | 0.48 | |||||
5-Year Yield-on-Cost % | 1.16 | |||||
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | 0.61 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.69 | |||||
Operating Margin % | 44.63 | |||||
Net Margin % | 33.79 | |||||
EBITDA Margin % | 52.25 | |||||
FCF Margin % | 41.62 | |||||
OCF Margin % | 42.02 | |||||
ROE % | 13.81 | |||||
ROA % | 12.55 | |||||
ROIC % | 98.81 | |||||
3-Year ROIIC % | 57.18 | |||||
ROC (Joel Greenblatt) % | 258.6 | |||||
ROCE % | 20.53 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 15.93 | |||||
Forward PE Ratio | 13.39 | |||||
PE Ratio without NRI | 15.93 | |||||
Shiller PE Ratio | 22.85 | |||||
Price-to-Owner-Earnings | 13.93 | |||||
PEG Ratio | 0.51 | |||||
PS Ratio | 5.38 | |||||
PB Ratio | 2.07 | |||||
Price-to-Tangible-Book | 2.07 | |||||
Price-to-Free-Cash-Flow | 12.94 | |||||
Price-to-Operating-Cash-Flow | 12.83 | |||||
EV-to-EBIT | 5.95 | |||||
EV-to-EBITDA | 5.82 | |||||
EV-to-Revenue | 3.04 | |||||
EV-to-Forward-Revenue | 2.83 | |||||
EV-to-FCF | 6.76 | |||||
Price-to-GF-Value | 0.58 | |||||
Price-to-Projected-FCF | 0.84 | |||||
Price-to-Median-PS-Value | 0.16 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.57 | |||||
Price-to-Graham-Number | 1.21 | |||||
| Price-to-Net-Current-Asset-Value | 2.14 | |||||
| Price-to-Net-Cash | 2.43 | |||||
Earnings Yield (Greenblatt) % | 16.8 | |||||
FCF Yield % | 7.63 | |||||
Forward Rate of Return (Yacktman) % | 25.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Clinuvel Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 96.303 | ||
| EPS (TTM) (A$) | 0.644 | ||
| Beta | 0.0237 | ||
| 3-Year Sharpe Ratio | -0.72 | ||
| 3-Year Sortino Ratio | -0.92 | ||
| Volatility % | 41.06 | ||
| 14-Day RSI | 61.6 | ||
| 14-Day ATR (A$) | 0.386594 | ||
| 20-Day SMA (A$) | 9.6965 | ||
| 12-1 Month Momentum % | -9.91 | ||
| 52-Week Range (A$) | 8.35 - 14 | ||
| Shares Outstanding (Mil) | 50.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Clinuvel Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Clinuvel Pharmaceuticals Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-10-16 10:00 | In 107 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-28 18:00 | In 58 days | ||
| Annual report for 2026 | 2026-08-28 | In 57 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 57 days | ||
| Second quarter earnings conference call for 2026 | 2026-02-26 18:00 | 11.41 (+2.79%) | ||
| Second quarter earnings results for 2026 | 2026-02-26 | 11.41 (+2.79%) | ||
| General meeting for 2025 | 2025-10-17 10:00 | 11.99 (+1.18%) | ||
| AUD 0.050000 Cash Dividend | 2025-09-04 | 10.40 (-0.48%) | ||
| Fourth quarter earnings conference call for 2025 | 2025-08-28 18:00 | 13.55 (-1.45%) | ||
| Annual report for 2025 | 2025-08-28 | 13.55 (-1.45%) |
Show
Entries
Clinuvel Pharmaceuticals Ltd Frequently Asked Questions
What is Clinuvel Pharmaceuticals Ltd(ASX:CUV)'s stock price today?
The current price of ASX:CUV is A$10.26. The 52 week high of ASX:CUV is A$14.00 and 52 week low is A$8.35.
When is next earnings date of Clinuvel Pharmaceuticals Ltd(ASX:CUV)?
The next earnings date of Clinuvel Pharmaceuticals Ltd(ASX:CUV) is 2026-08-28 Est..
Does Clinuvel Pharmaceuticals Ltd(ASX:CUV) pay dividends? If so, how much?
The Dividend Yield %  of Clinuvel Pharmaceuticals Ltd(ASX:CUV) is 0.48% (As of Today), Highest Dividend Payout Ratio of Clinuvel Pharmaceuticals Ltd(ASX:CUV) was 0.08. The lowest was 0.05. And the median was 0.07. The  Forward Dividend Yield % of Clinuvel Pharmaceuticals Ltd(ASX:CUV) is 0.48%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Clinuvel Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers